3 Leu. By analogy to the nomenclature describing abnormal hemoglobins, these are designated insulins Wakayama, Los Angeles, and Chicago, respectively (1). We demonstrate here that these mutations occur at contact sites between insulin and the ␣-subunit of the insulin receptor.
1
Mutations in human insulin cause an autosomal-dominant syndrome of diabetes and fasting hyperinsulinemia. We demonstrate by residue-specific photo crosslinking that diabetes-associated mutations occur at receptor-binding sites. The studies use para-azido-phenylalanine, introduced at five sites by total protein synthesis. Because two such sites (Val A3 and Phe B24 ) are largely buried in crystal structures of the free hormone, their participation in receptor binding is likely to require a conformational change to expose a hidden functional surface. Our results demonstrate that this surface spans both chains of the insulin molecule and includes sites of rare human mutations that cause diabetes. Diabetes 53:1599 -1602, 2004 T he insulinopathies describe a monogenic form of adult-onset diabetes due to mutations in the insulin gene (1, 2) . Patients respond normally to exogenous insulin but exhibit fasting mutant hyperinsulinemia due to delayed receptor-mediated clearance of the variant hormone (2) . Inheritance is autosomal dominant with variable penetrance. The presence of one wild-type allele permits normal growth and development; homozygous or hemizygous mutations have not been observed and are presumably incompatible with life. Diabetes-associated mutations may either impair binding of the variant insulin to its receptor or perturb subcellular trafficking and processing of the variant proinsulin in the pancreatic ␤-cell (2). Mutations that impair binding have been identified at three invariant sites: Val A3 3 Leu, Phe B24 3 Ser, and Phe B25 3 Leu. By analogy to the nomenclature describing abnormal hemoglobins, these are designated insulins Wakayama, Los Angeles, and Chicago, respectively (1). We demonstrate here that these mutations occur at contact sites between insulin and the ␣-subunit of the insulin receptor.
The structure of insulin is well characterized by crystallography (3) and nuclear magnetic resonance spectroscopy (4, 5) (Fig. 1A) , Tyr B16 , and Cys B19 to stabilize the supersecondary structure of the B-chain. In dimers and hexamers, Phe B24 and Phe B25 also participate in an intermolecular ␤-sheet, an essential element of insulin's storage form in the ␤-cell (3). Whereas considerable evidence indicates that the exposed side chain of Phe B25 contacts the insulin receptor (6, including previous photo crosslinking studies [7, 8] ), the roles of Val A3 and Phe B24 have long been the subject of speculation (3,9 -13) .
To test whether residues A3, B24, and B25 contact the insulin receptor, we have synthesized insulin analogs containing a photo-activatable derivative of phenylalanine (Phe), para-azido-Phe (Pap) (8, 14) . Pap was chosen based on its rigidity and small size (relative to other photoactivable moieties), thus limiting the distance range for cross-linking. Modified A-and B-chains were prepared by solid-phase synthesis using the photostable precursor para-amino-Phe. To enable efficient detection of crosslinked peptides, the ␣-amino group of the B-chain was biotinylated (8) . The nonstandard side chain was introduced into an engineered insulin monomer (DKP-insulin, which contains three B-chain substitutions: His 3 Pro), chosen as a template for its efficiency of synthesis, enhanced receptor binding, and absence of confounding self-association (4). A3, B24, and B25 para-amino-Phe analogs exhibit respective receptorbinding affinities of 2.0 Ϯ 0.2, 59 Ϯ 2, and 147 Ϯ 3% relative to native insulin (K d 0.48 nmol/l); the affinity of the biotin adduct of DKP-insulin is 132 Ϯ 5% (assays performed in triplicate). Corresponding analogs were prepared at terminal positions A1 and A21 (ordinarily conserved as Gly and Asn, respectively) at the periphery of insulin's putative receptor-binding surface (3, 15) ; their relative receptorbinding affinities are 46 Ϯ 5 and 79 Ϯ 22%. Asn A21 projects from the surface near Gly B23 and Phe B25 ( Fig. 2A) . Conversion of para-amino-Phe to Pap in the intact hormones was verified by mass spectrometry. A3, B24, and B25 Pap analogs each exhibit rapid and efficient cross-linking to the ectodomain of the receptor on ultraviolet irradiation (red asterisks in Fig. 1B and C) . Efficiency (defined as the probability of photo crosslinking of the Pap derivative once bound to the receptor) is highest for Pap A3 . Similar results are obtained with the lectin-purified holoreceptor. No covalent complex is observed in the absence of irradiation or in control studies of the para-amino-Phe B25 precursor. Photo cross-linking is successively diminished by the addition of native insulin or by higher concentrations of IGF-1 (Fig. 1D) . In contrast to the cross-linking at sites of clinical mutation, photo cross-linking of Pap derivatives at A1 and A21 is markedly less efficient (green arrows in lanes 6 and 14 in Fig. 1C ; relative to A3, complexes are reduced by 19-and 4-fold, respectively). As a first step in identifying sites of crosslinking in the insulin receptor, we used partial proteolysis with trypsin and chymotrypsin to characterize fragments of the receptor ␣-subunit covalently bound to insulin. Analysis of such fragments demonstrates that Pap (lanes 1, 2, 5, and 6) or samples not irradiated (lanes 1, 3, 5, and 7 2, 6, 10, and 14, respectively) analyzed without reduction. D: Specificity of photo cross-linking is indicated by competition using native insulin (lanes 1-6) or IGF-1 (lanes 7-12) hormone-receptor complex, followed by reduction with dithiothreitol (DTT), yields a 34-kDa adduct that, on further digestion, yields a 20-kDa adduct. Following enzymatic deglycosylation, the apparent mass of this fragment is 14 kDa and thus contains about 120 amino acids. The results of Kurose et al. imply that the latter fragment contains the COOH-terminal portion of the ␣-subunit derived from the second fibronectin-homology domain (FnIII 1 ) and insert domain (ID) (13) . Pap A3 , which is not predicted to contact the receptor in a current model based on electron-microscopic image reconstruction (16), cross-links the COOH-terminal to the L1 and cysteine-rich domains. To localize this site more precisely, a second Pap A3 derivative was prepared in which the biotin tag was attached at the NH 2 -terminus of the A-chain (rather than the NH 2 -terminus of the B-chain; see RESEARCH DESIGN AND METHODS). This design facilitates mapping following DTT reduction as above. Limited chymotryptic digestion thus demonstrates that Pap A3 crosslinks to the same COOH-terminal 34-kDa and 20-kDa adducts as Pap B25 , i.e., within the FnIII 1 -ID-derived tail. We suggest that the A3 binding site (like that of Pap B25 [8] ) resides within the ID-derived portion, since the FnIII 1 moiety may be deleted in active fragments of the ␣-subunit (13) . Because the L1 domain and the COOH-terminal domain are distant in the sequence of the ␣-subunit, the present results suggest that these and other sites of photo cross-linking are nearby in the three-dimensional structure of the hormone-receptor complex (13, 16 (3), it has been unclear whether these residues contact the receptor or serve as structural supports. A possible role for Phe B24 in redirecting the main chain of insulin on receptor binding has been proposed based on the unexpectedly high activities of D-amino acid substitutions (9) . We and others have hypothesized that detachment or reorganization of the COOH-terminal region of the B-chain near B24 exposes the side chains of Phe B24 and Val A3 and thus enables them to contact the receptor (11) (12) (13) 17) . The present results support (but do not establish) this hypothesis. Although we cannot exclude that Pap-mediated contacts are probe dependent (i.e., not ordinarily made by Phe B24 or Val A3 ), a direct interaction would rationalize the exquisite sensitivity of binding at each site to subtle modifications (such as  Tyr  B24 , Ala   A3 , Thr A3 , and Leu A3 ) (9, 10) . A direct interaction is consistent with the structure and function of a truncated insulin analog lacking the COOH-terminal five residues of the B-chain (residues B26 -B30) (magenta in Fig. 1A ). In the crystal structure of this analog, Val A3 is exposed in an otherwise native-like conformation (18) . When the new COOH-terminus is amidated, this analog is fully active (19) . Conversely, tethering the COOH-terminal segment of the B-chain to the A-chain yields a native-like single-chain analog with essentially no biological activity (17) . Furthermore, a conformational change in the B-chain would rationalize the low activity of a "chiral" analog in which the internal side chain of Ile A2 (also shielded by Tyr B26 and Pro B28 ) is substituted by allo-isoleucine (10) . This modification does not perturb the structure or stability of insulin but would alter its "hidden" functional surface (20) .
In the decades since the crystal structure of insulin was elucidated in 1969 by D. Hodgkin et al. (3) , the residues required for its function have been extensively investigated by mutagenesis and chemical modification (3, 13) . Interpretation of these results is incomplete, however, as such approaches do not generally distinguish between side chains that contact the receptor and those required to stabilize insulin's active conformation. By exploiting site- specific photo cross-linking, the present studies strongly suggest that sites of clinical mutations (1, 2) are in direct contact with the insulin receptor. A molecular understanding of such contacts, likely to emerge from a crystal structure of the hormone-receptor complex, may enable design of nonpeptide insulin agonists for the treatment of diabetes.
RESEARCH DESIGN AND METHODS
Insulin analogs were synthesized and purified as described (4, 8) . The relative receptor-binding affinities of para-amino-Phe analogs were determined by competitive displacement of 125 I-insulin from a human placental membrane preparation, as previously described (10) . Conversion of such analogs to Pap derivatives was effected as described (4) . Lectin-purification of the insulin receptor overexpressed in cell line P3-A was performed by the procedure of Yoshimasa et al. (21) . Photo cross-linking reactions were performed at high concentrations of hormone and receptor (ca. 200 nmol/l) to enable essentially complete binding of the Pap A3 analog. Short-wave ultraviolet light (254 nm) generated from a Mineralight Lamp (Model UVG-54; UVP, Upland, CA) was used with an optimum exposure time of 20 s and a distance of 1 cm from the light source. Identification of photo cross-linked receptor domains utilized prior characterization of chymotryptic and tryptic sites (22, 23) . Western blots used Neutravidin (Pierce, IL) and a polyclonal anti-receptor antiserum that recognizes the NH 2 -terminal region of the ␣ subunit (N-20; Santa Cruz Biotech, Santa Cruz, CA). For such mapping studies, analogs contained an aminocaproyl-biotin tag either at the ␣-amino group of residue B1 or, in the case of the second Pap A3 derivative, the ⑀-amino group of D-lysine introduced in place of glycine at position A1. Domain-mapping studies are supported by SDS-PAGE analysis of cross-linked fragments following enzymatic deglycosylation as described (24) .
